Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | THPO | P40225 | 1/20 | 0.82 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.77 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.77 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.77 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471250 | 0.96 | CACNA1F (0.83) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL7475992 | 0.95 | CACNA1F (0.82) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7273298 | 0.94 | MEN1 (0.76) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL10650021 | 0.94 | HIF1A (0.79) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9674179 | 0.94 | MEN1 (0.81) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9672384 | 0.93 | CACNA1F (0.80) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7280038 | 0.93 | CACNA1F (0.90) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9476417 | 0.93 | MEN1 (0.84) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9675670 | 0.92 | CACNA1F (0.80) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9672662 | 0.92 | CACNA1F (0.80) | HIF1AMEN1KMT2AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201558-A4 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES. | BRISTOL MYERS CO (US) | 1988-04-13 | — | — | EP | claimed |
| EP-0201558-A1 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES | Bristol-Myers Squibb Company (US) | 1986-11-20 | — | — | EP | claimed |
| WO-1986002640-A1 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES | BRISTOL-MYERS COMPANY (US) | 1986-05-09 | — | — | WO | claimed |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-5286869-A | Vasodilators and anticoagulants | FUJIREBIO KABUSHIKI KAISHA (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5258519-A | FOR TREATMENT OF HYPERTENSION AND CARDIAC CONDITIONS | GLAXO INC. (US) | 1993-11-02 | — | — | US | disclosed |
| EP-0250725-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | HEUMANN PHARMA GMBH & CO (DE) | 1992-11-04 | — | — | EP | disclosed |
| US-5100892-A | Hypotensive agents, congestive heart failure | GLAXO INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5063239-A | Cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-05 | — | — | US | disclosed |
| US-4994476-A | Hypotensive agents | BRISTOL-MYERS COMPANY (US) | 1991-02-19 | — | — | US | disclosed |
| US-4950676-A | HYPOTENSIVE AGENTS, CALCIUM ANTAGONISTS, TREATMENT OF ANGINA PECTORIS, VASODILATION | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-21 | — | — | US | disclosed |
| US-4861782-A | Certain 2h-benzo[a]quinolizin-2-yl-aminoalkyl esters of 1,4-dihydro-3,5-pyridinedicarboxylates useful for treating circulation disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | disclosed |
| EP-0320984-A2 | 1,4-Dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1989-06-21 | — | — | EP | disclosed |
| US-4757080-A | Pharmaceuticals | HEUMANN PHARMA GMBH & CO. (DE) | 1988-07-12 | — | — | US | disclosed |
| EP-0201558-A4 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES. | BRISTOL MYERS CO (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0250725-A1 | 1,4-Dihydropyridine derivatives, processes for their preparation and medicaments containing them | HEUMANN PHARMA GMBH & CO (DE) | 1988-01-07 | — | — | EP | disclosed |
| EP-0201558-A1 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES | Bristol-Myers Squibb Company (US) | 1986-11-20 | — | — | EP | disclosed |
| WO-1986002640-A1 | DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES | BRISTOL-MYERS COMPANY (US) | 1986-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | HIF1A 4473/4885MEN1 551/4885KMT2A 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.